FRANK CHING
IN mid-July, China’s state drug administration ordered Changsheng Bio-technology, a company headquartered in Changchun, in northeastern China, to stop production of rabies vaccines after it uncovered evidence of forged data. At about the same time, the company was fined 3.4 million yuan ($502,000) for the production of inferior DPT vaccines last year.